An estimated 80% of patients with systemic sclerosis (SSc) have pulmonary involvement, with interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) being the most common of these lung manifestations. In fact, both these conditions have been identified as the leading causes of SSc-related mortality. In this episode of the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress series, Toby Maher, MD, a professor of medicine and pulmonologist, describes the increased prevalence of lung involvement in scleroderma and the need for routine screening among these patients.

Ver todos los episodios